ARRDC2 Activators
ARRDC2 can initiate a cascade of intracellular events leading to its activation through various mechanisms, primarily involving the modulation of cAMP levels and subsequent activation of PKA, which is known to phosphorylate target proteins. Forskolin directly stimulates adenylyl cyclase, thereby increasing cAMP production. This elevation in cAMP facilitates the activation of PKA, which is then capable of phosphorylating ARRDC2. Similarly, IBMX, by inhibiting phosphodiesterases, prevents the degradation of cAMP, maintaining an environment conducive to PKA activation and subsequent ARRDC2 activation. Epinephrine and Isoproterenol, through their interaction with adrenergic receptors, both lead to the activation of adenylyl cyclase and a rise in cAMP levels, again promoting PKA activity and ARRDC2 phosphorylation.
Compounds like Rolipram and Zardaverine, by selectively inhibiting PDE4 and PDE3/PDE4 respectively, lead to an accumulation of cAMP within the cell, bolstering PKA activation and ARRDC2 phosphorylation. Salbutamol, Terbutaline, and L-858051, all beta-2 adrenergic receptor agonists, contribute to this process by specifically activating adenylyl cyclase, which increases cAMP and in turn, activates PKA, leading to the phosphorylation of ARRDC2. Prostaglandin E1 (PGE1) and Pituitary adenylate cyclase-activating polypeptide (PACAP-38) also engage in this signaling pathway; PGE1 through its own G protein-coupled receptor and PACAP-38 by binding to its receptor, both result in increased cAMP and subsequent PKA-mediated activation of ARRDC2. Cilostamide, akin to Rolipram and Zardaverine, selectively inhibits PDE3, sustaining cAMP levels and promoting PKA activity, which can then facilitate the phosphorylation and activation of ARRDC2. Collectively, these chemicals orchestrate a symphony of biochemical events that converge on the activation of ARRDC2 via phosphorylation by PKA.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in cyclic AMP (cAMP) levels which can enhance the activity of ARRDC2 by promoting cAMP-dependent protein kinase (PKA) activation. PKA can phosphorylate target proteins that may interact with and activate ARRDC2. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs) and prevents the breakdown of cAMP and cGMP, thereby sustaining their action. Sustained cAMP levels enhance PKA activity, which can phosphorylate and thereby activate ARRDC2. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine binds to adrenergic receptors, which leads to the activation of adenylyl cyclase and an increase in intracellular cAMP levels. Elevated cAMP activates PKA, which can subsequently activate ARRDC2 through phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that stimulates adenylyl cyclase activity, increasing cAMP production. This activation of the cAMP/PKA signaling pathway can lead to the phosphorylation and activation of ARRDC2. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which degrades cAMP. By inhibiting PDE4, rolipram increases cAMP levels, which enhances PKA activation and could lead to the activation of ARRDC2. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $30.00 $142.00 | 16 | |
Prostaglandin E1 (PGE1) activates its G protein-coupled receptor leading to an increase in cAMP production. Elevated cAMP activates PKA, which could lead to phosphorylation and activation of ARRDC2. | ||||||
PACAP(6-38) | 137061-48-4 | sc-391136 sc-391136A | 500 µg 1 mg | $529.00 $914.00 | ||
Pituitary adenylate cyclase-activating polypeptide (PACAP-38) binds to its GPCR, which activates adenylyl cyclase, thereby increasing cAMP levels. The resulting PKA activation may lead to phosphorylation and activation of ARRDC2. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $92.00 $138.00 | ||
Salbutamol is a selective beta-2 adrenergic agonist that stimulates adenylyl cyclase activity, increasing cAMP production. The increase in cAMP leads to activation of PKA, which can phosphorylate and activate ARRDC2. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $90.00 $371.00 | 2 | |
Terbutaline is a beta-2 adrenergic receptor agonist that increases intracellular cAMP levels by stimulating adenylyl cyclase. The activation of PKA by cAMP can result in phosphorylation and activation of ARRDC2. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a selective inhibitor of PDE3 and PDE4, leading to increased cAMP levels. The elevated cAMP activates PKA, which could lead to the phosphorylation and activation of ARRDC2. | ||||||